Today (14 May 2020), Net Health, a leading specialty health software firm with particularly successful market penetration in US wound clinics, announced the acquisition of Tissue Analytics. The entire TA team will remain and join the Net Health organization.
This development is significant to the advanced wound care and adjacent industries for many reasons. By integrating the TA platform and team, Net Health will now have (among others):
- The ability to follow patients across all care settings: From the hospital, to home, and everywhere in between (including even DME [durable medical equipment], which it has already integrated for many manufacturers and distributors).
- Best-in-class EMR integration competencies.
- Strong data and predictive analytics capabilities (TA Cofounder and CTO Josh Budman will assume a leadership role which includes predictive analytics).
- Powerful clinical trials capabilities, which can now leverage vast amounts data from a massive number of outpatient wound care clinics and other care settings, combined with rich product, procedure, and outcomes data.
- Partnerships across top industry players, which Net Health and Tissue Analytics had independently developed, will now benefit from economies of scale (technical, analytical, and commercial alike).
Tissue Analytics was backed by a broad range of institutional and strategic investors, including Dreamit Ventures, digiTx Partners, Chinese conglomerate Tencent, Mölnlycke Health Care, Intermountain Healthcare, and Penn Medicine.
Lastly, it was a great honor to serve on the Tissue Analytics board of directors for the past two years. I look forward to continuing to collaborate with the combined Net Health and Tissue Analytics organization in other ways, as they continue to drive innovation in the wound care and specialty health IT space.